• Title, Summary, Keyword: 제약회사

Search Result 265, Processing Time 0.031 seconds

마우스 골수세포와 말초혈액을 이용한 Giemsa와 Acridine orange를 이용한 염색법 비교

  • 박지은;이성학;최재묵;김일환;김택로;노현정;김영훈
    • Proceedings of the Korean Society of Toxicology Conference
    • /
    • /
    • pp.47-47
    • /
    • 2003
  • Acridine orange를 이용한 염색법은 OECD guideline 474에 채택되어 널리 사용되고 있는 염색법으로 Giemsa를 이용하였을 때 보다 artifact를 구별하기 쉬우며 숙련되지 않는 관찰자도 쉽게 소핵을 구별할 수 있다는 장점을 가지고 있다. 본 시험에서는 신약의 초기 screening단계에서 유전독성여부를 알아보기 위한 방법으로 마우스 골수세포와 말초혈액을 이용하여 Geimsa와 Acridine orange염색법을 비교하였다. (중략)

  • PDF

돼지 췌장 유래 엘라스타제의 변이원성 시험

  • 조영우;백남기;안병욱;이상득;박충일;김원배;양중익
    • Environmental Mutagens and Carcinogens
    • /
    • v.10 no.2
    • /
    • pp.107-112
    • /
    • 1990
  • 돼지 췌장 유래 엘라스타제의 돌연변이원성을 알아보기 위하여 포유동물 세포를 이용한 돌연변이 시험과 마우스를 이용한 소핵시험을 실시하였다. 엘라스타아제에 의하여 CHO-K1-BH4 cell이 6-thioguanine에 대해 내성을 가지게 되는 변이의 빈도를 조사하였다. 시험결과 엘라스타아제의 농도 증가 (0-30mg/ml)에 따른 변이빈도의 증가가 관찰되지 않았으며, 변이빈도도 음성대조군 변이빈도 치의 2배 이상을 보이지 않았다. 마우스를 이용한 소핵시험에서는 엘라스타아제를 1250, 2500 그리고 5000mg/kg의 용량으로 마우스에 1회 경구 투여 하였으며 양성대조군과 음성대조군에는 각각 mitomycin C 2mg/kg, 10skim milk 20ml/kg 을 각각 복강내와 경구로 투여하였다. 시험결과 엘라스타제 투여군의 소핵 출현빈도는 음성대조군과 비교하여 증가하지 않았다. 위의 결과로 보아 엘라스탄제는 이 시험계들에서 돌연변이원성이 없는 것으로 사려된다.

  • PDF

돼지 췌장 유래 엘라스타제의 항원성 시험

  • 김순희;백남기;이상득;김원배;양중익;안병옥;이순복
    • Environmental Mutagens and Carcinogens
    • /
    • v.10 no.2
    • /
    • pp.113-118
    • /
    • 1990
  • 엘라스타제를 기니픽에 감작시킨 후에 항체검출시험을 실시하였다. 감작은 경구투여 및 피하주사의 두가지 방법으로 하였다. 경구감작은 투여직전 엘라스타제를 생리식염수에 용해한 후 강제투여하였으며, 피하감작은 엘라스타제를 Freund's complete adjuvant 에 현탁시킨 후, 목 뒷부분에 주사하였다. 항체생성의 양성, 음성 검출은 경구감작군에 대해, 능동적전신성아나필랙시 (ASA번)과 면역확산번 (ID법)으로, 피하감작군에 대해 수신피부아나필랙시 (PCA법)으로 행하였다. 결과, 경구감작군은 임상용량 (180 Unit/kg)의 경우는 ASA법 및 ID법 모두에서 음성을 보였으나, 임상 10배용량의 경우는 ASA법에서는 양성을 보인 동물이 있었으나 통계학적 우의성은 없었으며 (p<0.1), ID법에서는 음성을 보였다. 피하감작군은 모든 투여군에서 PCA양성을 보였다. 결론적으로 엘라스타제는 항원성이 인정되나, 임상용량을 경구적으로 투여한 경우는 항원성이 나타나지 않았다.

  • PDF

Pharmaceutical Companies to Enhance Brand Identity and Package Design for the Improvement (브랜드 아이덴티티 강화를 위한 제약회사 패키지디자인 개선방안 모색)

  • Jin, Jung-Oh;Baek, Kyung-Duck
    • Proceedings of the KAIS Fall Conference
    • /
    • /
    • pp.996-999
    • /
    • 2011
  • 패키지디자인은 상품이 다양화 되고 선택의 기회와 폭이 넓어지면서 소비자는 감성적 가치에 치중하게 되었다. 본 연구는 건강식품브랜드 패키지디자인 개발을 통하여 제약회사 패키지 개발의 특수성과 제작에 있어서 개선방안을 모색하고자 하였다. 연구대상인 제약회사 패키지 디자인은 첫째, 엄브렐러 브랜드(umbrella brand) 정책을 실시하고 있었다. 둘째, 보령 수앤수(보령 건강식품브랜드)의 브랜드 아이덴티티 부재이다. 셋째, 패키지 디자인에있어 규제가 많아서 시각적으로 보기 좋은 패키지 디자인을 하기 어려운 부분이 있다. 제약회사는 규모와 투자여력에 비하여 패키지 디자인에 투자하지 않는 영세성의 문제점을 가지고 있다. 국제적인 제약회사가 패키지 디자인에 강력한 시각적 아이덴티티 정책을 실시하고 있음을 양지하고 이를 개선하는 방안을 모색해야 한다.

  • PDF

Subacute Toxicity of DA-125, A New Anthracycline Anticancer Agent in Rats (새로운 Anthracycline 항암제 DA-125의 랫드에서의 아급성독성연구)

  • 이순복;백남기;안병옥;김옥진;강경구;이철용;김원배;양중익
    • Biomolecules & Therapeutics
    • /
    • v.1 no.2
    • /
    • pp.226-235
    • /
    • 1993
  • DA-125, a new anthracycline antitumor antibiotic, was administered to Sprague-Dawley rats intravenously for 4 weeks to investigate the repeated dose toxicity Focal alopecia was noted in three female rats receiving 1.0mg/kg/day. In rats receiving 1.0 mg/kg/day, weight gain decreased in both sexes after first or second week. Hematological examination revealed lower counts of total leukocyte and increased numbers of platelet after second week. At terminal necropsy, atrophy of thymus and spleen was observed. Lymphocytic depletion of thymus and atrophy of white pulp in spleen were observed microscopically. A decrease in the number of hematopoietic cells in the bone marrow and degeneration of germinal epithelia in testes were also observed. These treatment-related effects were mainly confined to rats receiving 1.0 mg/kg/day. And toxic effects with microscopic changes were not observed in rats receiving 0.2 mg/kg/day or 0.04 mg/kg/day.

  • PDF

General Pharmacology of DA-5018, a New Capsaicin Derivative (새로운 캅사이신유도체 DA-5018외 일반약리작용)

  • 김순희;손문호;신명수;김희기;배은주;차봉진;김원배;양중의
    • Biomolecules & Therapeutics
    • /
    • v.5 no.1
    • /
    • pp.74-81
    • /
    • 1997
  • DA-5018(N-(3-(3, 4-dimethylphenyl)propyl)-4-(2-aminoethoxy)-3-methoxyphenylacetamide) is a new capsaicin derivative under development as topical analgesic agent. The general pharmacological properties of DA-5018 on central nervous, cardiovascular, gastrointestinal and other organ systems were studied in experimental animals. DA-5018 cream (0.3%) had no effects on behavior, hexobarbital-induced sleeping time, body temperature, spontaneous activity, blood pressure, heart rate, intestinal charcoal propulsion, urine volume and electrolyte excretion even at a high dose of 2000 mg/kg in rats. In addition, DA-5Ol8 cream had little skin irritation compared to Zostrix-HP (capsaicin, 0.075%) cream in rabbits. In isolated guinea pig tissue studies, DA-5018 increased the contractility of trachea and ileum and also increased sinus rate of atrium in a range of 10^{-8}-10^{-5}$$ M, but its efficacy as a agonist was weak. These results suggest that DA-5018 cream might be used topically without serious side effects.

  • PDF

Analgesic Components of the Rhizoma of Astilbe chinensis var. davidii (노루오줌 근경의 진통성분)

  • Oh, Kap-Jin;Choi, Yun-Seuk;Choi, Il-Shik;Park, Si-Kyung;Lee, Kyou-Heung;Chung, Sun-Gan;Cho, Eui-Hwan
    • YAKHAK HOEJI
    • /
    • v.36 no.5
    • /
    • pp.474-480
    • /
    • 1992
  • Astilbes rhizoma has been used for headache, arthralgia, chronic bronchitis and stomachalgia in traditional chinese medicine. The analgesic activities and their components of Astilbe chinensis var. davidii Rhizomes were evaluated. The ether and ethylacetate fractions of 70% EtOH extract showed considerable analgesic activities by acetic acid induced writhing method. Compound $1{\sim}5$ were isolated from ethylacetate fraction and identified as gallic acid, (+)-catechin, (+)-gallocatechin, bergenin and 11-O-galloylbergenin on the basis of spectroscopic methods. Among them (+)-gallocatechin showed stronger analgesic activity than that of other compounds.

  • PDF

Efficacy and General Pharmacology of Recombinant Human Erythropoietin(DA-3285) (Recombinant Human Erythropoietin(DA-3285)의 효력 및 일반약리작용)

  • 김동환;안병옥;손문호;신명수;이성희;김원배;양중익
    • Biomolecules & Therapeutics
    • /
    • v.4 no.1
    • /
    • pp.68-77
    • /
    • 1996
  • Efficacy and general pharmacology of recombinant human erythropoietin (rHu-EPO), were investigated. Efficacy studies were conducted in normal, cisplatin- and acute hemorrhage-induced anemic rats. Normal and anemic animals were treated intravenously with rHu-EPO for 5 days and the changes in the numbers of red blood cells (RBC), hemoglobin (Hb), hematocrit (Hct) and reticulocytes (Ret) were examined. In normal rats, rHu-EPO significantly increased RBC, Hb, Hct and Ret at doses of 50∼ 1250 IU/kg/day. Cisplatin-induced anemic rats showed significant increase of RBC, Hb, Hct and Ret in a dose-dependent manner after administration of rHu-EPO (50∼200 lU/kg/day). And in acute hemorrhage-induced anemic rats, rHu-EPO(4∼100 Iu/kg/day) accelerated recovery of anemia with significant increase in Ret. These changes disappeared gradually after cessation of the treatment. The general pharmacological effects of rHu-EPO were investigated in mice, rats, guinea-pigs, rabbits and cats. rHu-EPO had no influences on central nervous, cardiovascular, gastrointestinal and blood coagulation system. It also had no influence on the contraction of phrenic nerve-diaphragm preparation. rHu-EPO produced significant increase of urine volume at a dose of 7000 IU/kg. These results suggest that rHu-EPO might be useful for the therapy of anemia without serious side effect.

  • PDF

A Study on Integrated Physical Distribution of the Pharmaceutical Industry in Korea (한국제약산업의 통합물류에 관한 연구)

  • Kwon, Oh-cheul;Youn, Myoung-kil;Namkung, Suk
    • Journal of Distribution Science
    • /
    • v.5 no.2
    • /
    • pp.17-34
    • /
    • 2007
  • The Korean pharmaceutical industry has many pharmaceutical companies and business acquaintances, small quantity batch production and a lot of competition products having same ingredient. Under such a situation, an integrated distribution is said to be proper to lower distribution costs and deliver effectively: However, each business has different delivery conditions, timely delivery of small quantity batch order and other particular services, etc to have problems of competition of turnover increase. The study suggests measures below to lower distribution costs and to elevate sales business efficiency. First, Joint marketing of pharmaceuticals between pharmaceutical companies. Second, Joint delivery of three or less companies having similar business scales. Third, An agreement with wholesale distributors of unified distribution of pharmaceuticals being sold much. Fourthly, Wholesale distributors' pharmaceuticals distribution services. Fifthly, Cooperation of business acquaintance. In summary, the Korean pharmaceutical industry needs an integrated distribution system. Considering characteristics of the industry, however, the small pharmaceutical companies are thought to be difficult to accept the integrated distribution because complete integrated distribution may reduce sales.

  • PDF